Floatz logo

cd19-ucart

Diffuse Large B Cell Lymphoma

Chongqing Precision Biotech Co., LtdCell therapyPhase 1/2Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
73/ 100

Competitive context

270 Active assets in the Diffuse Large B Cell Lymphoma cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 2/3A
Evomela
Ruijin Hospital
Phase 4BBB
Axicabtagene Ciloleucel
Ruijin Hospital
Phase 4BBB
PREDNISONE TABLETS
Beth Israel Deaconess Medical Center
Phase 4BBB
Inno-206
Beth Israel Deaconess Medical Center
Phase 4BBB

View all 50 →

Same molecule, other indications

cd19-ucart is also rated in:

B-Cell Acute Lymphoblastic Leukemia, AdultDormant
BBB
Indicative ·
72 / 100
View asset →
B-cell non-Hodgkin lymphomaDormant
BB
Indicative ·
71 / 100
View asset →
B-cell acute lymphoblastic leukemiaDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →